Maze Therapeutics (NASDAQ:MAZE) Trading Up 4.8% – Here’s Why

Maze Therapeutics, Inc. (NASDAQ:MAZE) shares were up 4.8% during trading on Tuesday . The company traded as high as $12.13 and last traded at $12.04. Approximately 31,787 shares changed hands during mid-day trading, a decline of 87% from the average daily volume of 244,637 shares. The stock had previously closed at $11.49.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on MAZE shares. Guggenheim started coverage on Maze Therapeutics in a research note on Tuesday, February 25th. They issued a “buy” rating and a $19.00 target price for the company. TD Cowen upgraded Maze Therapeutics to a “strong-buy” rating in a research note on Tuesday, February 25th. JPMorgan Chase & Co. initiated coverage on Maze Therapeutics in a research note on Tuesday, February 25th. They set an “overweight” rating and a $30.00 price objective for the company. Leerink Partnrs upgraded Maze Therapeutics to a “strong-buy” rating in a research note on Tuesday, February 25th. Finally, Leerink Partners initiated coverage on Maze Therapeutics in a report on Tuesday, February 25th. They issued an “outperform” rating and a $28.00 target price for the company. Three research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Maze Therapeutics currently has a consensus rating of “Buy” and an average price target of $25.67.

Maze Therapeutics Stock Performance

About Maze Therapeutics

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.